keyword
https://read.qxmd.com/read/38535092/performance-of-a-novel-eight-color-flow-cytometry-panel-for-measurable-residual-disease-assessment-of-chronic-lymphocytic-leukemia
#1
JOURNAL ARTICLE
Xiao Chen, Xia Chen, Sishu Zhao, Yu Shi, Ninghan Zhang, Zhen Guo, Chun Qiao, Huimin Jin, Liying Zhu, Huayuan Zhu, Jianyong Li, Yujie Wu
BACKGROUND: Measurable residual disease (MRD) is an important prognostic indicator of chronic lymphocytic leukemia (CLL). Different flow cytometric panels have been developed for the MRD assessment of CLL in Western countries; however, the application of these panels in China remains largely unexplored. METHODS: Owing to the requirements for high accuracy, reproducibility, and comparability of MRD assessment in China, we investigated the performance of a flow cytometric approach (CD45-ROR1 panel) to assess MRD in patients with CLL...
March 27, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38345199/enhancing-hla-b27-antigen-detection-leveraging-machine-learning-algorithms-for-flow-cytometric-analysis
#2
JOURNAL ARTICLE
Sándor Baráth, Parvind Singh, Zsuzsanna Hevessy, Anikó Ujfalusi, Zoltán Mezei, Mária Balogh, Marianna Száraz Széles, János Kappelmayer
As the association of human leukocyte antigen B27 (HLA-B27) with spondylarthropathies is widely known, HLA-B27 antigen expression is frequently identified using flow cytometric or other techniques. Because of the possibility of cross-reaction with off target antigens, such as HLA-B7, each flow cytometric technique applies a "gray zone" reserved for equivocal findings. Our aim was to use machine learning (ML) methods to classify such equivocal data as positive or negative. Equivocal samples (n = 99) were selected from samples submitted to our institution for clinical evaluation by HLA-B27 antigen testing...
February 12, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38345160/flow-cytometry-of-dnmt1-as-a-biomarker-of-hypomethylating-therapies
#3
JOURNAL ARTICLE
Philip G Woost, Basem M William, Brenda W Cooper, Masumi Ueda Oshima, Folashade Otegbeye, Marcos J De Lima, David Wald, Reda Z Mahfouz, Yogen Saunthararajah, Tammy Stefan, James W Jacobberger
The 5-azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation-inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid leukemias (AML), and under evaluation as maintenance therapy for AML postallogeneic hematopoietic stem cell transplant and to treat hemoglobinapathies. Malignant cell cytoreduction is thought to occur by S-phase specific depletion of the key epigenetic regulator, DNA methyltransferase 1 (DNMT1) that, in the case of cancers, thereby releases terminal-differentiation programs...
February 12, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38297808/role-of-flow-cytometric-immunophenotyping-in-the-diagnosis-of-breast-implant-associated-anaplastic-large-cell-lymphoma-a-6-year-single-institution-experience
#4
REVIEW
Alexander Chan, Romany Auclair, Qi Gao, Paola Ghione, Steven Horwitz, Ahmet Dogan, Mikhail Roshal, Oscar Lin
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon mature T-cell neoplasm occurring in patients with textured breast implants, typically after 7-10 years of exposure. Although cytopathologic or histopathologic assessment is considered the gold standard diagnostic method for BIA-ALCL, flow cytometry (FC)-based immunophenotyping is recommended as an adjunct test. However, the diagnostic efficacy of FC is not well reported. We reviewed 290 FC tests from breast implant pericapsular fluid and capsule tissue from 182 patients, including 16 patients with BIA-ALCL over a 6-year period, calculating diagnostic rates and test efficacy...
March 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38217297/standardization-of-flow-cytometric-detection-of-antigen-expression
#5
JOURNAL ARTICLE
Linhua Tian, Aaron R Nelson, Tyler Lowe, Linda Weaver, Constance Yuan, Hao-Wei Wang, Paul DeRose, Maryalice Stetler-Stevenson, Lili Wang
Since response to antigen-based immunotherapy relies upon the level of tumor antigen expression we developed an antigen quantification assay using ABC values. Antigen quantification as a clinical assay requires methods for quality control and for interlaboratory and inter-cytometer platform standardization. A single lot of Cytotrol™ Lyophilized Control Cells (Beckman Coulter) used for all studies. The variability in antigen quantification across 4 different instrument platforms in 2 separate laboratories was evaluated...
January 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38010113/an-alternative-processing-approach-to-increase-cd138-intensity-in-flow-cytometric-analysis-of-plasma-cells
#6
JOURNAL ARTICLE
Deepak Kumar, F N U Kiran, Amanda Wheeler, Rory Dellamano, Richard D Hammer
BACKGROUND: Surface median immunofluorescence intensity (MFI) of plasma cells antigens, particularly CD138, by flow cytometry underestimates plasma cell populations when compared with that estimated by morphological assessment on Wright's-stained slides. CD138 MFI using traditional sample preparation methods for flow cytometric analysis is often dim and difficult to interpret due to multiple factors. This becomes critical when diagnosing and accurately classifying plasma cell dyscrasias...
March 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/37933409/flow-cytometric-analysis-of-cd34-cd38-cells-cell-frequency-and-immunophenotype-based-on-cd45ra-expression-pattern
#7
JOURNAL ARTICLE
Shumpei Mizuta, Makoto Iwasaki, Noriko Bandai, Saya Yoshida, Asami Watanabe, Hiroshi Takashima, Takeshi Ueshimo, Kazuhiro Bandai, Kensuke Fujiwara, Naoko Hiranuma, Yusuke Koba, Takahito Kawata, Akira Tamekane, Mitsumasa Watanabe
INTRODUCTION: The CD34+ CD38- population in bone marrow includes hematopoietic stem/progenitor cells. Recently, in acute myeloid leukemia, the focus has shifted to flow cytometry analysis targeting CD34+ CD38- leukemic cells due to their effectiveness in minimal/measurable residual disease detection and prognosis prediction. Nevertheless, the immunophenotype and cell frequency of these cells in the bone marrow, in the absence of leukemic cells, remains unknown. We aimed to evaluate detailed characteristics of CD34+ CD38- cells in both normal and leukemic cells by flow cytometry...
November 6, 2023: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/36931661/serpin-b9-controls-tumor-cell-killing-by-car-t-cells
#8
JOURNAL ARTICLE
Thomas Kimman, Anne Slomp, Anne Martens, Sarah Grabherr, Shuang Li, Eline van Diest, Jan Meeldijk, Jurgen Kuball, Monique C Minnema, Eric Eldering, Niels Bovenschen, Zsolt Sebestyén, Victor Peperzak
BACKGROUND: Initial clinical responses with gene engineered chimeric antigen receptor (CAR) T cells in cancer patients are highly encouraging; however, primary resistance and also relapse may prevent durable remission in a substantial part of the patients. One of the underlying causes is the resistance mechanisms in cancer cells that limit effective killing by CAR T cells. CAR T cells exert their cytotoxic function through secretion of granzymes and perforin. Inhibition of granzyme B (GrB) can underlie resistance to T cell-mediated killing, and it has been shown that serine proteinase inhibitor serpin B9 can effectively inhibit GrB...
March 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/36683279/flow-cytometric-assessment-for-minimal-measurable-residual-disease-in-b-lymphoblastic-leukemia-lymphoma-in-the-era-of-immunotherapy
#9
REVIEW
Xueyan Chen, Qi Gao, Mikhail Roshal, Sindhu Cherian
Minimal/measurable residual disease (MRD) is the most important independent prognostic factor for patients with B-lymphoblastic leukemia (B-LL). MRD post therapy has been incorporated into risk stratification and clinical management, resulting in substantially improved outcomes in pediatric and adult patients. Currently, MRD in B-ALL is most commonly assessed by multiparametric flow cytometry and molecular (polymerase chain reaction or high-throughput sequencing based) methods. The detection of MRD by flow cytometry in B-ALL often begins with B cell antigen-based gating strategies...
January 22, 2023: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/36595922/flow-cytometric-protocol-to-characterize-human-memory-b-cells-directed-against-sars-cov-2-spike-protein-antigens
#10
JOURNAL ARTICLE
Leonie M Weskamm, Christine Dahlke, Marylyn M Addo
Memory B cells (MBCs), part of the immune response elicited by infection or vaccination, can persist in lymphoid organs and peripheral blood and are capable of rapid reactivation upon secondary antigen exposure. Here, we describe a flow cytometric assay to identify antigen-specific MBCs from peripheral blood mononuclear cells and characterize their isotypes and activation status. We detail steps to use fluorescently labeled antigen probes derived from the SARS-CoV-2 spike protein. These can be adapted to detect MBCs against other antigens...
December 16, 2022: STAR protocols
https://read.qxmd.com/read/36416672/multicenter-prospective-evaluation-of-diagnostic-potential-of-flow-cytometric-aberrancies-in-myelodysplastic-syndromes-by-the-eln-imds-flow-working-group
#11
MULTICENTER STUDY
Wolfgang Kern, Theresia M Westers, Frauke Bellos, Marie Christine Bene, Peter Bettelheim, Lisa Eidenschink Brodersen, Kate Burbury, Sung-Chao Chu, Matthew Cullen, Matteo Della Porta, Alan Stewart Dunlop, Ulrika Johansson, Sergio Matarraz, Uta Oelschlaegel, Kiyoyuki Ogata, Anna Porwit, Frank Preijers, Katherina Psarra, Leonie Saft, Dolores Subirá, Elisabeth Weiß, Vincent H J van der Velden, Arjan van de Loosdrecht
BACKGROUND: Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre-defined flow cytometric markers in the diagnostic work-up of MDS and chronic myelomonocytic leukemia (CMML). METHODS: Thousand six hundred and eighty-two patients with suspected MDS/CMML were analyzed by both cytomorphology according to WHO 2016 criteria and flow cytometry according to ELN recommendations. Flow cytometric readout was categorized 'non-MDS' (i...
January 2023: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/36321879/mature-b-and-plasma-cell-flow-cytometric-analysis-a-review-of-the-impact-of-targeted-therapy
#12
REVIEW
Qi Gao, Xueyan Chen, Sindhu Cherian, Mikhail Roshal
Flow cytometry has been indispensable in diagnosing B cell lymphoma and plasma cell neoplasms. The advances in novel multicolor flow cytometry have also made this technology a robust tool for monitoring minimal/measurable residual disease in chronic lymphocytic leukemia and multiple myeloma. However, challenges using conventional gating strategies to isolate neoplastic B or plasma cells are emerging due to the rapidly increasing number of antibody therapeutics targeting single or multiple classic B/plasma cell-lineage markers, such as CD19, CD20, and CD22 in B cells and CD38 in plasma cells...
November 2, 2022: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/36279192/a-comprehensive-assessment-of-four-whole-blood-stabilisers-for-flow-cytometric-analysis-of-leukocyte-populations
#13
JOURNAL ARTICLE
Ngoc Anh Nguyen, Xiaobo Huang, Luz E Cabrera, Pirkka T Pekkarinen, Kirsten Nowlan, Tomas Strandin, Anu Kantele, Olli Vapalahti, Santtu Heinonen, Eliisa Kekäläinen
Though cryopreservation of cell fractions is widely used in flow cytometry studies, whole blood cryopreservation is more challenging due to the presence of erythrocytes and effects of fixatives commonly used for preservation. Here, we evaluated and compared head-to-head the performance of four commercial whole blood cryopreservation kits; 1) Cytodelics, 2) Stable-Lyse V2 and Stable-Store V2 (SLSS-V2), 3) Proteomic stabiliser (PROT-1), and 4) Transfix. We found that PROT-1, Transfix and Cytodelics maintained the distribution of major leukocyte subsets - granulocytes, T cells, natural killer cells and B cells, on a comparable level to unpreserved samples, despite the attenuation of fluorescence intensities in flow cytometric assays...
October 24, 2022: Cytometry. Part A: the Journal of the International Society for Analytical Cytology
https://read.qxmd.com/read/36189252/development-of-a-standardized-and-validated-flow-cytometry-approach-for-monitoring-of-innate-myeloid-immune-cells-in-human-blood
#14
JOURNAL ARTICLE
Kyra van der Pan, Sandra de Bruin-Versteeg, Daniela Damasceno, Alejandro Hernández-Delgado, Alita J van der Sluijs-Gelling, Wouter B L van den Bossche, Inge F de Laat, Paula Díez, Brigitta A E Naber, Annieck M Diks, Magdalena A Berkowska, Bas de Mooij, Rick J Groenland, Fenna J de Bie, Indu Khatri, Sara Kassem, Anniek L de Jager, Alesha Louis, Julia Almeida, Jacqueline A M van Gaans-van den Brink, Alex-Mikael Barkoff, Qiushui He, Gerben Ferwerda, Pauline Versteegen, Guy A M Berbers, Alberto Orfao, Jacques J M van Dongen, Cristina Teodosio
Innate myeloid cell (IMC) populations form an essential part of innate immunity. Flow cytometric (FCM) monitoring of IMCs in peripheral blood (PB) has great clinical potential for disease monitoring due to their role in maintenance of tissue homeostasis and ability to sense micro-environmental changes, such as inflammatory processes and tissue damage. However, the lack of standardized and validated approaches has hampered broad clinical implementation. For accurate identification and separation of IMC populations, 62 antibodies against 44 different proteins were evaluated...
2022: Frontiers in Immunology
https://read.qxmd.com/read/36134740/immunophenotypic-assessment-of-pnh-clones-in-major-and-minor-cell-lineages-in-the-peripheral-blood-of-patients-with-paroxysmal-nocturnal-hemoglobinuria
#15
JOURNAL ARTICLE
Stephen J Richards, Anita J Dickinson, Darren J Newton, Peter Hillmen
BACKGROUND: Flow cytometric immunophenotyping is essential for the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). Most cases have easy to interpret flow cytometry profiles with red cells, neutrophils and monocytes showing complete deficiency of glycophosphatidylinositol (GPI) linked antigen expression. Some cases are more challenging to interpret due to the presence of multiple populations of PNH cells and variable levels of GPI antigen expression. METHODS: We studied 46 known PNH patients, many with complex immunophenotypic profiles using a novel, single tube, multi-parameter 7-color immunophenotyping assay that allowed simultaneous detection and assessment of PNH clones within multiple lineages of peripheral blood leucocytes...
November 2022: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/36070226/external-quality-assessment-of-flow-cytometric-bronchoalveolar-lavage-cellular-analysis-20-years-experience-in-the-netherlands
#16
JOURNAL ARTICLE
A H Leontine Mulder, Harrie H M Eidhof, Jan W Gratama
BACKGROUND: Bronchoalveolar (BAL) cellular analysis can be supportive in the diagnosis of interstitial lung disease. The flow cytometric analysis of BAL fluid cells is complicated by cell fragility and adherence and autofluorescence of macrophages, making conventional analysis of BAL fluid cells as done in external quality schemes (EQA) for blood lymphocyte subsets, not representative. Following a procedure for stabilized BAL cells, a separate EQA was set up. The results of 20 years' experience are presented...
September 7, 2022: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/35796438/b-lineage-antigens-that-are-useful-to-substitute-cd19-for-minimal-residual-disease-monitoring-in-b-cell-precursor-acute-lymphoblastic-leukemia-after-cd19-targeting
#17
JOURNAL ARTICLE
Ekaterina Mikhailova, Albert Itov, Elena Zerkalenkova, Julia Roumiantseva, Yulia Olshanskaya, Alexander Karachunskiy, Galina Novichkova, Michael Maschan, Alexander Popov
BACKGROUND: The potential loss of CD19 during targeted treatment of B cell precursor acute lymphoblastic leukemia (BCP-ALL) can hamper flow cytometric minimal residual disease (MRD) monitoring. In the current study, we present expression data for antigens that are candidates for CD19 substitution: surface CD22, CD24, CD10, and intracellular (i) CD79a. METHODS: Bone marrow samples from 519 consecutive children (below 18 y.o.) with primary BCP-ALL were studied with a focus on expression of CD19, CD10, CD22, CD24, and iCD79a...
September 2022: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/35735203/immunophenotypic-characteristics-of-znf384-rearrangement-compared-with-bcr-abl1-kmt2a-rearrangement-and-other-adult-b-cell-precursor-acute-lymphoblastic-leukemia
#18
JOURNAL ARTICLE
Ya-Zhe Wang, Ya-Zhen Qin, Yan Chang, Xiao-Ying Yuan, Wen-Min Chen, Ling-Ling He, Le Hao, Wei-Hua Shi, Qian Jiang, Hao Jiang, Xiao-Jun Huang, Yan-Rong Liu
BACKGROUND: ZNF384 rearrangement has been recently identified as a new subtype of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive studies clarifying immunophenotypic features and discriminating them from non-ZNF384 in adult BCP-ALL remain scarce to date. METHODS: Flow cytometric assessments were retrospectively performed in 43 patients with ZNF384 rearrangement, 45 with BCR-ABL1, 29 with KMT2A rearrangement and 44 with other BCP-ALL in the analysis cohort...
September 2022: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/35716019/acute-promyelocytic-leukemia-immunophenotype-and-differential-diagnosis-by-flow-cytometry
#19
JOURNAL ARTICLE
Hong Fang, Sa A Wang, Shimin Hu, Sergej N Konoplev, Huan Mo, Wei Liu, Zhuang Zuo, Jie Xu, Jeffrey L Jorgensen, C Cameron Yin, Siba El Hussein, Fatima Zahra Jelloul, Zhenya Tang, L Jeffrey Medeiros, Wei Wang
BACKGROUND: Prompt diagnosis of acute promyelocytic leukemia (APL) is critical for patient care. In this study, we aimed to characterize the immunophenotype of APL and explore immunophenotypic difference between APL and its mimics using flow cytometric analysis. METHODS: Eighty-five cases were collected, including 47 APL, 26 NPM1-mutated acute myeloid leukemia (AML) and 12 KMT2A-rearranged AML with an APL-like immunophenotype. Immunophenotypes were analyzed using flow cytometric analysis...
July 2022: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/35661398/cd200-expression-on-sezary-cells-a-valuable-tool-for-flow-cytometric-assessment-of-peripheral-blood-t-cell-neoplasms
#20
JOURNAL ARTICLE
Afshin Shameli, Tariq M Roshan
BACKGROUND: CD200 (OX-2) is a valuable marker in the diagnosis of B-cell neoplasms and is commonly used in the screening panels for assessment of peripheral blood B-cell lymphoproliferative disorders. However, there is limited understanding about CD200 expression in T-cell neoplasms. A previous study has shown that CD200 is expressed on the neoplastic cells of angioimmunoblastic T-cell lymphoma (AITL) by immunohistochemistry, but no study has evaluated CD200 expression in T-cell neoplasms by flow cytometry...
July 2022: Cytometry. Part B, Clinical Cytometry
keyword
keyword
163455
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.